业绩亮点：- 收入及纯利分别达78.9百万美元及18.8百万美元。- 亚太地区市场收入显著增长31.0%，主要受惠于内部增长，以及于2023年第四季收购的韩国分销商SJ Medicare及印尼分销商PT Revass所带来的贡献。- 自有产品的总销量维持在717,000件。- 于2024年上半年，集团将去年收购的德国公司eucatech AG与集团的营运整合，并重组其生产线，预期eucatech AG将于第三季度恢复生产及出货。- 集团一直积极在多个国家及地区注册eucatech AG的产品，其中，冠状动脉药物洗脱支架eucaLimus已于马来西亚获批准注册。- TricValve的临床研究方面，OrbusNeich P&F已为该产品于中国13家医院展开病人入组。在日本，集团正与医药品医疗机器综合机构（「PMDA」）及美国食品药品监督管理局（「FDA」）紧密合作，为该产品的临床测试及注册程序作准备。- 于2024年5月，集团已为旗下位于杭州的最大研发及生产设施委聘总承建商，预期于2027年投产，届时将为集团的年产能增加240万件产品。- 于2024年6月30日，集团的财务状况稳健，现金及银行结余达246.7百万美元。- 集团预期维持稳定的股息政策，显示对前景充满信心。香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司（「业聚医疗」或「集团」；股份代号：6929）今天宣布截至2024年6月30日止六个月(「报告期」)的中期业绩。尽管面对不同的市场挑战，集团的收入及本公司拥有人应占期内利润仍分别保持于78.9百万美元及18.8百万美元的水平。业聚医疗董事长、执行董事兼行政总裁钱永勋先生表示：「由于地缘政治局势紧张及主要央行货币政策转变等因素，全球经济近年一直非常动荡。尽管外围环境充满挑战，我们仍能把握契机，采取一系列措施提高营运效率，并将去年收购的SJ Medicare、PT Revass 及eucatech AG与集团的业务整合。我们相信，上半年所作的投资对于支持集团未来可持续增长至关重要。」报告期内，尽管亚太地区的销售录得大幅增长，以及日本市场以日圆计价收入也达到温和增长，然而，由于Abbott Laboratories（「雅培」）对Cardiovascular Systems, Inc. (「CSI」)进行整合令美国销量下跌、中国市场受到反腐运动持续影响，以及集团终止分销若干第三方产品，集团的收入微跌3.1%至78.9百万美元。若撇除外汇波动影响，总收入按年微升0.6%。毛利为55.8百万美元，毛利率达70.7%。尽管收入下降，以及集团为提高营运效率及整合去年收购的业务而采取了一系列措施，导致短期开支增加，但2024年上半年的纯利仍维持稳健。值得一提的是，若撇除新收购业务的营运开支，2024年上半年的销售及分销开支、一般及行政开支及研发开支三项核心营运开支的水平，事实上与去年同期相若。截至2024年6月30日，集团的财务状况稳健，现金及银行结余达约246.7百万美元，为支持集团达致增长目标奠定坚实基础。亚太地区及欧洲、中东及非洲地区球囊销售表现强劲集团的自有球囊产品继续深受全球欢迎。2024年上半年，有赖马来西亚、香港、印度、越南及新加坡等市场的球囊销售额增长强劲，带动亚太地区市场收入取得8.6%的自然增长。特别是最新一代刻痕球囊Scoreflex TRIO，自2024年初在马来西亚推出以来，销量迅速攀升。这加上集团在2023年第四季收购的韩国分销商SJ Medicare及印尼分销商PT Revass在期内带来4.3百万美元的额外收入贡献，推动亚太地区的总收入同比大升31.0%至24.0百万美元。此外，主要受惠于集团的自有球囊产品在直销市场，如德国、法国及西班牙，以及分销市场，如捷克及斯洛伐克的销量有所增加，即使集团与CSI终止有关旋磨产品的分销协议抵销了部分收入升幅，来自欧洲、中东及非洲的收入仍增加1.3%至19.2百万美元。2024年上半年，Scoreflex TRIO继续推动集团最大单一地域市场――日本的收入增长，按日圆计价，较去年同比增长8.1%。整合新收购业务　推动未来增长继2023年11月收购eucatech AG后，集团积极投入各项工作，致力将eucatech AG整合至集团营运，并重组其生产线。集团积极在多个国家及地区注册eucatech AG旗下eucaLimus、Support C、Resistant及VITUS四款产品，以便透过集团自身的销售网络，向不同市场的医生及患者提供这些产品。2024年上半年，eucaLimus于集团的直销市场马来西亚获批准注册，而eucatech AG其他产品的注册申请亦已提交予香港、马来西亚、瑞士、意大利及沙特阿拉伯的相关监管机构，正等待批准。此外，为稳步提升eucatech AG旗下产品上市后的销量，集团于EuroPCR等重要会议上进行推广，并向分销商提供有关产品的资讯。2024年4月，集团为eucatech AG接受关于医疗器械指令（「MDD」）及医疗器械条例（「MDR」）现场监督审核提供支援，从而在MDD框架下延长上述四款产品的CE标志到期日。通过以上举措，eucatech AG有望于今年第三季恢复生产及出货。致力将创新理念转化为丰富的产品线截至2024年6月30日，业聚医疗共有逾50款获批产品。集团一直坚持将研发成果转化为成功商业化的产品，至今已实现多个重大里程碑，包括：- Teleport Neuro获得NMPA批准；Teleport XT、JADE PLUS 14/18/35 OTW获FDA批准；Sapphire ULTRA及Sapphire NC ULTRA取得CE标志；- 向国家药监局提交导引导管注册申请；- Scoreflex TRIO在中国的临床测试病人入组完成，预计将于2024年第三季向国家药监局提交申请；- 现正为Sapphire 3美国临床测试做准备，并计划于2024年第三季在美国开始进行病人入组。除上述监管及商业化工作外，集团亦继续投资于新产品管线，例如Corepass模组化微导管、支撑导管及JADE Plus，并预计于2024年向各监管机构提交该三种创新产品的注册申请。与此同时，合资企业OrbusNeich P&F于两个主要亚太区市场大力推进TricValve临床研究。在中国，临床测试已展开病人入组；而在日本，OrbusNeich P&F与PMDA及FDA紧密合作，准备于日本进行TricValve临床测试及注册。透过严格质量控制及卓越运营流程提升产能集团重视产品质量，并以严格的质量管理系统把关。报告期内，集团多个生产基地顺利通过了不同监管机构及认证机构的审核。此外，集团亦持续优化生产流程、半成品库存及人员的生产力，以提升营运效率及降低生产成本。为满足未来生产所需，集团于中国杭州市兴建旗下最大的研发生产设施，并已于2024年5月委聘总承建商，预期于2027年投产，届时将为集团的年产能增加240万件产品。钱先生总结道：「展望未来，我们预期集团在中国及美国两大主要地域市场实施新销售策略后，此两大巿场将能在今年下半年重拾增长动力。与此同时，我们亦会继续拓展市场据点。产品方面，我们会利用完善的销售网络及品牌知名度，推广创新的血管介入产品， 致力为医生提供更佳的解决方案。而随着eucatech AG即将恢复生产，其新增至集团的产品亦有助加强我们的盈利能力。我们亦正积极物色符合集团策略重点的并购机会，以进一步推动集团可持续增长。尽管上半年面临诸多挑战，我们仍对迅速恢复增长势头保持乐观，并期望在稳健的财务基础上，为股东维持稳定的股息政策。」— 完 —关于业聚医疗集团控股有限公司业聚医疗是一家主要的全球医疗器械制造商，专门生产用于经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）的介入器械。业聚医疗的总部位于中国香港，产品销往全球超过70个国家和地区。集团亦积极将业务扩展至神经血管介入及结构性心脏病领域。截至2024年6月30日，业聚医疗已于全球拥有超过230项授权专利及已公布专利申请，其内部研发团队拥有逾20年的产品开发经验，并已开发出世界领先的专有技术。如需了解更多详情，请访问集团官网：https://orbusneich.com/ Copyright 2024 亚太商讯 via SeaPRwire.com.

Results Highlights:- Revenue and net profit reached US$78.9 million and US$18.8 million, respectively.- APAC market revenue grew significantly by 31.0%, driven by both organic growth and contributions from SJ Medicare and PT Revass, the South Korean and Indonesian distributors acquired in Q4 2023.- Total sales volume of proprietary products remained at 717,000 units.- In 1H2024, the Group made extensive efforts to integrate eucatech AG, a German company acquired last year, into its operations and reorganize its production lines, and expects eucatech AG to resume production and shipment in Q3.- The Group has been actively registering products of eucatech AG in various countries and regions, and eucaLimus, a coronary drug eluting stent, has already received registration approval in Malaysia.- For the clinical studies of TricValve, patient enrollment has commenced in 13 hospitals in the PRC. In Japan, the Group is working closely with the Pharmaceuticals and Medical Devices Agency (“PMDA”) and the US Food and Drug Administration (“FDA”) to prepare for the clinical trial and registration process.- In May 2024, the Group engaged the main contractor for its largest R&D and manufacturing facility in Hangzhou, which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million product units upon commencement of production.- The Group’s financial position remained strong, as evidenced by the cash and bank balances of US$246.7 million as of June 30, 2024.- The Group expects to maintain a stable dividend policy, demonstrating its confidence in future prospects.HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2024 (the “Reporting Period”), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “The global economy has been highly volatile in recent years, as a result of factors such as geopolitical tensions and major central banks shifting their monetary policies. Albeit the challenging external environment, we were able to seize the opportunity to implement a series of measures to enhance operational efficiency and integrate the businesses of SJ Medicare, PT Revass and eucatech AG acquired last year into our Group. We believe the investments made in the first half year are crucial to supporting our future sustainable growth.”For the Reporting Period, the Group’s revenue decreased slightly by 3.1% to US$78.9 million, mainly attributable to decline in sales volume in the US due to integration of Cardiovascular Systems, Inc. (“CSI”) into Abbott Laboratories (“Abbott”), and in the PRC market due to on-going impact of anti-corruption campaign, as well as the Group’s termination of distribution of certain third-party products, despite the significant sales growth recorded in APAC, as well as the modest revenue growth in Japan in terms of Japanese Yen. Excluding the impact of the foreign exchange fluctuations, total revenue would have recorded a slight year-on-year increase of 0.6%. Gross profit amounted to US$55.8 million while gross profit margin stood at 70.7%.Despite the decline in revenue and the short-term increase in expenses incurred by the Group’s series of measures to enhance operational efficiency and integrate the businesses acquired in the previous year, the Group maintained a healthy level of net profit for the first half of 2024. It is worth noting that, excluding the operating expenses of the newly acquired businesses, the three core operating expenses, namely selling and distribution expenses, general and administrative expenses and research and development expenses, for the first half of 2024, remained flat against the same period last year. As of June 30, 2024, the Group maintained a strong financial position with cash and bank balances of approximately US$246.7 million, laying a solid foundation to support its growth objective.Robust Balloon Sales in APAC and EMEAThe Group’s proprietary balloon products continued to gain traction worldwide. In the first half of 2024, revenue from the APAC market saw organic growth of a marked 8.6% year-on-year, thanks to strong balloon sales growth in markets such as Malaysia, Hong Kong, India, Vietnam and Singapore. Particularly, the latest generation of scoring balloon, Scoreflex TRIO, recorded a rapid rise in sales since it was launched in Malaysia in early 2024. Together with the additional contribution of US$4.3 million from the SJ Medicare and PT Revass, distributors acquired in South Korea and Indonesia respectively in Q4 2023, the revenue generated from APAC amounted to a total of US$24.0 million, representing a significant increase of 31.0% year-on-year.In addition, mainly attributable to the increase in sales of the Group’s proprietary balloon products in direct sales markets such as Germany, France and Spain, as well as distributor sales markets including Czech Republic and Slovakia, revenue generated from EMEA slightly increased by 1.3% to US$19.2 million, even being partly offset by the termination of distribution agreement with CSI for atherectomy products.During the first half of 2024, Scoreflex TRIO continued to drive revenue generated from Japan, the Group’s largest single-country market, in terms of Japanese Yen, achieving an 8.1% increase year-on-year.Integrating Newly Acquired Business to Drive Future GrowthFollowing the acquisition of eucatech AG in November 2023, extensive efforts were made to integrate eucatech AG into the Group’s operation and reorganize production lines. The Group has been actively registering eucatech AG’s four products, namely eucaLimus, Support C, Resistant, and VITUS, in various countries and regions to avail those products via the Group’s own sales network to physicians and patients in different markets. In the first half of 2024, eucaLimus was granted registration approval in Malaysia, one of the Group’s direct sales markets. Registration applications for eucatech AG’s products have also been submitted to relevant regulatory bodies in Hong Kong, Malaysia, Switzerland, Italy and Saudi Arabia and are pending approval. The Group also promoted eucatech AG’s products at major conferences including EuroPCR, as well as educated distributors about these offerings so that sales could be ramped up smoothly once the products become available.In April 2024, the Group supported eucatech AG’s on-site Medical Device Directive (“MDD”) and Medical Device Regulation (“MDR”) surveillance audit, as such, was able to extend the CE Mark expiration dates for their 4 products under the MDD framework. All these efforts are expected to see eucatech AG resume production and shipment in the third quarter of the year.Relentless Drive to Translate Innovations into Thriving Product LinesAs of June 30, 2024, OrbusNeich had an aggregate of over 50 approved products. The Group has maintained a steadfast commitment to translating its R&D efforts into commercially successful products. To date, the Group achieved major milestones, including:- Obtaining NMPA approval for Teleport Neuro, FDA approval for Teleport XT and JADE PLUS 14/18/35 OTW, CE Mark for Sapphire ULTRA and Sapphire NC ULTRA;- Submission of registration applications to the NMPA for its Guiding Catheter;- Completion of the clinical trial patient enrollment for Scoreflex TRIO in the PRC, with the NMPA application expected to be submitted in Q3 2024;- Preparation for the Sapphire 3 clinical trial in the US, with enrollment scheduled to begin in Q3 2024.Alongside these regulatory and commercialization efforts, the Group continued to invest in new pipeline products, such as the Corepass modular microcatheter, support catheter and the JADE Plus. Registration applications for these innovative offerings are planned for submission to various authorities in 2024.Meanwhile, the joint venture OrbusNeich P&F made significant efforts to advance the clinical studies of TricValve in two major Asia Pacific markets. Patient enrollment has commenced in the PRC for its clinical trial, and the clinical trial and registration process in Japan is being prepared in close collaboration with the PMDA and the FDA.Boosting Production Capacity through Rigorous Quality Processes and Operational ExcellenceThe Group has always prioritized product quality, which is ensured by a robust quality management system. During the Reporting Period, various sites successfully passed audits conducted by various regulatory and notifying bodies. Furthermore, the Group remains committed to enhancing operational efficiency and reducing production costs by continually optimizing manufacturing processes, work-in-progress inventory levels, and employee productivity. To meet future production needs, the Group will construct its largest R&D and manufacturing facility in Hangzhou, the PRC, for which it engaged the main contractor in May 2024 and which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million units of products upon commencement of production.Mr. Chien concluded: “Looking ahead, as new sales strategies are being executed in the PRC and the US markets, we expect these key geographies will regain growth momentum in second half of the year. Meanwhile, OrbusNeich has maintained active efforts to expand our market presence. On the product front, we are leveraging our comprehensive sales network and brand recognition to market innovative endovascular intervention products to enhance the solutions we provide to the physicians. New products from eucatech AG which is expected to resume production soon will also contribute to improved profitability. We are also actively identifying M&A opportunities that align with our strategic priorities and position us for sustainable growth. Despite the first-half headwinds, we remain optimistic about restoring growth momentum soon and expect to maintain a stable dividend policy for shareholders based on our robust financial position.”- End -About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As of June 30, 2024, OrbusNeich has more than 230 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 2024年8月15日，康哲药业发布2024年中期业绩公告，整体营业额和期间利润环比去年下半年稳步提升。2024年上半年实现营收36.11亿元，同比下降21.7%，环比增长6.1%；若全按药品销售收入计算营收42.88亿元，同比下降22.6%，环比增长8.9%；其中，非国采独家产品及创新产品合计销售收入为人民币24.05亿元，占全按药品销售收入计算营业额的56.1%。实现净利润9.03亿元，同比下降52.8%，环比大幅增长92.8%。2024年，正值康哲药业创新产品商业化的开局之年，也是国家带量采购（国采）对其业绩影响得以释放的关键节点。因黛力新进入第七批国采目录，于2022年11月执行；波依定和优思弗进入第八批国采目录，于2023年7月开始执行；且三款原研药品均未中标，对公司经营业绩带来负面影响。2024年上半年，公司整体业绩环比去年下半年呈现增长态势，标志着康哲药业已基本消化国采影响，成功迈入由非国采独家产品和创新产品驱动业务增长的“新产品时代”。随着莱芙兰（亚甲蓝肠溶缓释片）于今年6月获批上市，美泰彤（甲氨蝶呤注射液）增加成人活动性类风湿关节炎适应症于7月获批上市，康哲药业处于商业化阶段的创新药组合已扩充至5款产品（含6项适应症），并有丰富的差异化创新管线储备。聚创新之能，乘发展之势，康哲药业正以更健康的产品结构全面塑造发展新动能，进一步迎接高质量发展新周期。“合作+自主”双擎研发模式驱动管线量质齐升，加速创新科研成果转化深厚的创新药研发管线是康哲药业长期发展的重要驱动力。公司以坚持满足临床未尽之需，解决患者用药之困为创新目的，以“合作研发+自主研发”双擎驱动，不断布局FIC（全球首创）与BIC（同类最佳）创新产品，并提升研究与临床开发的能力与效率，实现医药科研成果社会和商业价值的快速转化。截至目前，康哲药业中国获批上市的创新产品组合已扩充至5款产品（含6项适应症），其中4款创新药（维图可、益路取、美泰彤-银屑病适应症、维福瑞）已获纳入国家医保目录，并进入规模化临床应用；并新增创新药莱芙兰、美泰彤（类风湿关节炎）在中国获批上市。康哲药业亦稳步推进创新产品临床开发相关工作。目前，德昔度司他片正处于中国NDA审评中；合计约10个项目即将开展/正在推进以注册性随机对照试验（RCT）为主的临床试验。同时，公司不断强化基础研究和自主创新能力，目前已顺利推进10余项自主研究项目，其中三款创新药（VEGFA+ANG2四价双特异性抗体、高选择性TYK2抑制剂CMS-D001片、及GnRH受体拮抗剂CMS-D002胶囊）已进入临床开发阶段。此外，公司创新管线不断扩充。今年3月，康哲药业与Incyte再度达成合作，获得选择性小分子口服JAK1抑制剂povorcitinib在中国大陆、香港、澳门、台湾地区及东南亚11国等国家/地区的研究、开发、注册及商业化产品的独家许可权利，进一步丰富公司在白癜风和其他免疫介导皮肤病治疗领域的产品组合。接下来，康哲药业每年将持续以更高效率、更可控成本源源不断产出创新产品，加速创新价值释放，通过以非国采独家产品和创新产品为主导的健康产品结构，迎接高质量、可持续的业绩增长。成功的商业化体系，高效协同创新产品临床价值释放深耕专科领域32年，成功的商业化能力是康哲药业核心竞争力之一。通过持续强化与整合“开放式商业化平台”，已实现心脑血管/消化、皮肤、眼科三大独立运营业务深入发展，并在关联领域扩张边界；已建立强执行力、高素质的专业推广团队、广泛的渠道与资源覆盖，为公司创新产品实现快速市场准入与品牌塑造奠定了坚实基础。康哲药业四款已进入大规模临床应用的创新药，覆盖中枢神经、皮肤、肾内、消化系统等相关疾病领域，与原有品种在团队和渠道等方面协同增效发展。同时，凭借已获纳入国家医保目录的契机，公司正大力推动医院开发、品牌力建设，真实世界研究，及围绕医学驱动的学术推广工作；并结合患者援助及科普教育项目，提升患者对创新药可及性，推动创新产品临床价值释放。皮肤医美业务“康哲美丽”以皮肤治疗处方产品为核心，轻医美产品和皮肤学级护肤品为延展，不断完善皮肤治疗、皮肤护理和医疗美容全生命周期皮肤健康管理平台。在皮肤处方药临床开发方面，已完成磷酸芦可替尼乳膏白癜风适应症的关键真实世界研究，正在推进中国大陆注册上市申请工作。同时，持续补充再生类轻医美产品矩阵，其中童颜针的中国医疗器械注册申请已于报告期内获受理；并新获三款处于中国注册性临床阶段的再生类轻医美产品，“少女针”、“微晶瓷”、及脱细胞基质植入剂的中国商业化独占许可权利。业绩公告显示，截至6月底，康哲药业推广网络覆盖中国超5.5万家医院及医疗机构，约28万家终端零售药店。通过在心脑血管、消化、中枢神经系统、肾内科、眼科、皮肤科等专科领域优势积累，康哲药业稳步释放专科业务规模效益，高筑业务竞争壁垒，持续构建自身优势专科治疗领域护城河，为多款创新产品和独家品种的商业化带来广阔前景。擘画国际化布局，为增量市场蓄势聚力东南亚业务公司“康联达健康”整合集团化优势资源，将康哲药业在中国市场的成功经验、全球优质产品和创新技术资源外溢共享到东南亚，加速完善东南亚业务“研产销”一体化的开放式平台，为中国和全球药企高质量“出海”战略赋能，也为康哲药业打开更大的增量发展空间。截至6月底，康联达健康已建立有竞争力的产品组合，拥有十余款差异化品种，覆盖肿瘤、中枢神经、自免、皮肤科、眼科等疾病领域。康联达健康正加速推进多款创新储备产品在东南亚各国的上市申请和注册相关工作，如芦可替尼乳膏、亚甲蓝肠溶缓释片、地西泮鼻喷雾剂等；并与君实生物正共同推动特瑞普利单抗（抗PD-1单抗）于东南亚多国的注册进程，以期尽快惠及当地肿瘤患者。去年12月，康哲药业、康联达健康携手康龙化成等共同促成了新加坡生产工厂的收购。今年，各方正持续有序推进该生产工厂的设备检测、质量核查、生产质量体系认证等系列工作，旨在加速CDMO业务进程，并进一步优化集团海外供应链和生产能力。此布局将助力康哲药业未来与全球合作伙伴开展更多产业间合作，共同构建共赢互惠的开放式医疗创新生态。结语自1992年创立至今，康哲药业顺延行业发展脉络，以前瞻性视野成功推动了三次意义重大的战略转型。公司起步于进口原研药品的代理，逐步发展至控制原研/独家成熟产品权利，再到实现了全面创新转型，每一步都踏在产业发展迭代的节奏中。征程万里风正劲，康哲药业目标如炬，不断垒筑发展厚度，构建穿越周期的韧性。如今，随着国采对公司业绩的影响逐步释放，康哲药业已焕然一新，在拥抱阶段性创新成果的同时，以更充分的准备去迎接未来更长远、更健康的发展。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化业务竞争力，并将皮肤医美、眼科业务独立运营，培育专科小领域的大龙头，提升专科规模效率。同时业务版图拓展至东南亚市场，着力成为全球药企进军东南亚市场的“桥头堡”，助力康哲药业高质量持续健康发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及本集团的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。本集团并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，本集团对该等第三方声明及预测不承担责任。 Copyright 2024 亚太商讯 via SeaPRwire.com.

BRISBANE, AUS, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO FSI ANZ 2024 invites cybersecurity professionals in the Financial Services Industry to join this free virtual event designed to inspire and share intelligence. The online gathering will cover everything from cyber strategy, risk management, governance, program and incident management, leadership, to enabling business growth.CISO FSI ANZ offers a unique opportunity to expand your knowledge and find ways to avoid cyber threats in the FSI industry. Benchmark your strategies with peers and learn how to get buy-in and collaboration in your projects across the board.Key topics include:Strategies to advance your company’s cyber security maturity modelsHow to align cyber risk management with the company's goalsComplying with APRA regulations in Australia and MBIE in New ZealandThe impacts of the privacy act reform in information securitySuccessful practices to mitigate the increase of third-party risksBridging the talent gap by investing in culture, education and trainingNavigating the “AI high” by leveraging its benefits while minimising its risksCISO FSI ANZ is an essential online event for those looking to advance their knowledge and network within the cybersecurity community. Join us on 12 September 2024 at 10 AM AEDT or 12 PM NZT.It’s free! Register now: https://bit.ly/4dpyOUYVisit website: https://ciso-fsi-anz.coriniumintelligence.com/About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

CANBERA, AUSTRALIA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO Canberra invites cyber security professionals to explore the critical role of public sector cyber security in protecting the public and driving transformative leadership strategies for delivering the 2023-2030 Australian Cyber Security Strategy.The tech demo exhibition will showcase cutting-edge services and innovations driving change in the cybersecurity landscape. InfoSec leaders will share their strategic insights in no-nonsense talks, providing valuable substance over empty rhetoric.Key themes include:STRENGTH IN UNITY: Building robust shields against cyber threats by navigating the 2023-2030 Australian Cyber Security Strategy to be the most secured nation.AWARENESS, EMPOWERMENT, & COORDINATION: Maturing cyber security culture through collective responsibility and collaborative efforts for enhanced resilience.PROACTIVE GRC MANAGEMENT: Integrating Zero Trust and evaluating risks in supply chains, data and AI to empower decision making at the pace of innovation.MODERNISING THREAT DETECTION & RESPONSE: Embracing cutting-edge technologies and strategies to advance security, integrity and resilience capabilities.CISO Canberra 2024 is an essential event for those looking to advance their knowledge and network within the cybersecurity community. Join us at the Canberra Rex Hotel on 14 November 2024 for an event that promises to inspire and empower.Use the code ACNNEWS20 for 20% off the ticket price.Register here: https://bit.ly/4dqzPfbVisit website: https://ciso-bris.coriniumintelligence.com/ About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

财务业绩摘要- 上半年，集团录得以下经营成果：  – 收入上升2.3%至143.45亿元人民币；毛利率上升1.6个百分点至50.4%  – 经营现金净流入上升40.6%至27.30亿元人民币  – 本公司权益持有人应占净溢利为19.52亿元人民币，净利率为13.6%，息税前利润加折旧及摊销率为24.0%- 运营资金保持健康水平：  – 平均运营资金总额占收入比为7.1%  – 现金循环周期为31天，比去年同期增加1天- 董事会决议宣派截至2024年6月30日止六个月之中期股息每股已发行或于可换股证券转换后将予发行的本公司普通股37.75分人民币经营业绩摘要- 整体零售流水（包括线上及线下）录得低单位数下降- 渠道库存同比上升中单位数，库存周转与库龄结构保持在健康水平- 新品线下零售流水录得中单位数下降香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 李宁有限公司（香港联交所股份代号：2331（港币柜台）及82331（人民币柜台））今天宣布集团截至2024年6月30日止六个月之中期业绩。财务业绩2024年上半年，中国经济展现出有序的复苏态势，国家政策利好持续为市场注入活力。国民健康意识不断提升大背景，伴随多项国际性及国家级体育赛事的到来，催化了民众运动热情。目前，整体消费信心仍具恢复空间，市场正在逐步良性调整中。期内，集团依托品牌的专业运动基因，充分发挥运动行业洞察力、运动品类理解力及科技创新研发力，专注于跑步、篮球、健身、羽毛球和运动生活五大核心品类。通过持续的研发投入和科技创新，不断推动产品力的升级，优化消费者体验，确保集团在保持业务扩展的同时，实现长期可持续的发展。2024年上半年，集团整体业绩平稳，务实发展。期内，集团收入达143.45亿元人民币，较2023年同期上升2.3%（2023年上半年：140.19亿元人民币）。毛利较2023年同期的68.39亿元人民币上升5.8%至72.36亿元人民币，集团整体毛利率为50.4%，较去年同期上升1.6个百分点（2023年上半年：48.8%）。每股基本收益为75.80分人民币（2023年上半年：80.63分人民币）。董事会决议宣派截至2024年6月30日止六个月之中期股息，每股已发行或于可换股证券转换后将予发行的本公司普通股37.75分人民币（2023年上半年：36.20分人民币），中期派息比率为50%。现金流管理方面，期内经营活动产生之现金净额为27.30亿元人民币（2023年上半年：19.42亿元人民币）。于2024年6月30日之现金及等同现金项目（包括银行现金及手头现金，以及原到期日不超过三个月的定期存款）为61.47亿元人民币，较2023年12月31日净增加7.03亿元人民币。加回被记录在银行定期存款中的金额，现金余额为175.58亿元人民币，较2023年12月31日净减少4.17亿元人民币。期内，收入同比增长，回款效率保持稳定，同时集团合理安排采购及付款计划，促成经营活动产生之现金净额同比上升，集团将持续以现金流管理作为重点工作，以保证公司长期稳定的发展。经营概要期内，集团秉持「单品牌、多品类、多渠道」的核心战略，聚焦七大业务变革赛道，持续强化运动基因，明确品牌专业运动定位，并在供应链管理、物流平台、渠道拓展以及门店升级方面高效赋能，共同构筑了集团整体销售的坚实基础。在科技创新方面，2024年5月，集团成功举办「以我为名，科技李宁」主题科技大会，展现集团在长期科技创新积累之下，形成的科技研发及运动科学研究两大产品研发创新支柱，并展示集团的六大创新科技：「碳核芯」、「最速曲线系统」、「超级弜」、「GCU」、「超级䨻」、「极限䨻丝」，同时亦首次发布三大创新成果：「绝影3」跑鞋、顶级竞速跑鞋「龙雀」、防暴雨双透纳米科技。专业产品与营销方面，集团继续专注于跑步、篮球、羽毛球、健身和运动生活五大核心品类，持续在运动科技创新方面发力，同时亦积极与运动潮流文化接轨，推出兼具科技与时尚属性的运动产品，不断增强产品的核心竞争力。此外，集团积极布局全域营销，加强消费者对集团产品的认知，不断提升品牌影响力，扩大消费者基础。体育大年背景下，集团推出「以我为名」主题活动，鼓励每个人成为运动主角，从传递品牌主张和精神，到国家金牌队运动员、多品类顶级运动员及运动KOL的运动者故事，再到李宁科技实力的整体展现、主题系列产品推出、终端主题氛围打造，夯实李宁品牌的专业形象，实现从品牌主张到产品体验的全链路，深度连接品牌与每一个消费者。供应链管理方面，集团构建了全方位、高效能的供应链生态体系，不仅深度挖掘并扩充了高端运动与户外产品的优质供应商资源，形成强大的供应商矩阵，更以柔性供应策略为核心，灵活应对市场变化。物流管理方面，集团采用精细化物流计划管理，根据事业部特点定制策略，优化货品入仓与发货流程。同时，物流信息化平台赋能经销商，实时共享信息，提高门店配货效率，物流服务的质量进一步提升。渠道拓展与形象升级方面，集团积极优化渠道布局，通过关闭低效店铺并强化优质店铺的改造与拓展，巩固并扩大在高层级市场的竞争优势。同时，新兴市场的积极开拓，九代店铺的全新升级，以及超级奥莱的成功打造，均进一步提升品牌形象与市场影响力。为了营造沉浸式的关键赛事体验，上半年已有4,238家门店引入「以我为名」主题活动和核心运动资源的关键视觉陈列设计，进一步增强消费者的视觉感受和品牌认知。截至2024年6月30日，李宁牌（包含李宁核心品牌及李宁YOUNG）常规店、旗舰店、中国李宁时尚店、LI-NING 1990店、工厂店、品牌集合店的销售点数量为7,677家，较2023年12月31日净增加9家；经销商44家（包括中国李宁时尚店渠道），较2023年12月31日净减少2家，展现集团在渠道布局上的精准和高效。在零售运营方面，上半年集团深化单店经营模式的创新与实践，有效推动零售运营标准的全面落地。通过终端门店销售计划系统的全面推进与核心门店的系统落地，实现门店管理效率的显著提升。在新零售业务方面，集团通过数字化转型，强化社群运营和内容创造，实现私域流量的高效转化，销售额与转换效率均实现有效提升。此外，集团积极探索多元化商业模式，包括通过抖音等社交平台引流及与核心渠道的线上业务合作，不断为终端销售注入新动力，提升门店的离店销售占比，进一步增强门店经营效率。在电商运营方面，李宁电商继续专注于专业功能类产品的突破，尤其在跑步鞋领域实现快速增长，专业实战篮球鞋产品亦巩固了市场领先地位；此外，在线上专供单品领域，集团成功打造多款在业界获得体量与口碑的单品。期内，集团通过线上线下渠道的有效整合与创新实践，实现电商业务与零售运营的协同增长，推动销售业绩的显著提升和市场份额的进一步加强。童装业务方面，李宁YOUNG对青少年产品矩阵进行深入梳理，明确服装和配饰的核心竞争力，完善鞋类产品矩阵。营销方面，李宁YOUNG整合市场营销资源，积极探索全渠道营销及社群运营，并通过与篮球明星韦德合作，提升品牌影响力；积极开展各类会员社群活动、打造全新的运动明星进店开业活动，助力门店引流。截至2024年6月30日，于中国，李宁YOUNG销售点数量共计1,438个，较上一季末净增加33个，本年迄今净增加10个。集团将继续深入发展李宁YOUNG业务，聚焦产品，提升产品核心科技与设计，深耕市场需求及品类规划，同时强化品牌推广，推动李宁YOUNG成为中国儿童首选的专业运动童装品牌。前景展望集团将继续践行「单品牌、多品类、多渠道」的核心战略，不断强化产品力，并通过整合营运资源，务求以高效的企业组织能力，推动集团实现稳健且持续的增长：– 基本面业务稳健发展：集团将持续深化李宁品牌的市场影响力，重点发展跑步、篮球、健身、羽毛球和运动生活五大核心品类。通过研发创新投入，实现产品矩阵的持续升级，以满足消费者对高质量、个性化运动装备日益增长的需求，巩固并扩大集团在核心领域的市场领导地位；– 产品结构优化升级：集团将进一步升级单品牌战略下多元化的产品矩阵，顺应市场趋势和消费者偏好的演变，充分发挥「中国李宁」及「LI-NING 1990」在运动生活领域的补充作用，拓展多元的穿搭场景，增强品牌在多元场景下的竞争力；– 放眼未来择机破局：集团将积极探索破局，率先切入体育消费新赛道，挖掘女子、户外和青少年市场的巨大潜力，制定针对性的营销策略，推出符合目标群体需求的产品，力求在这些新领域取得突破；– 优化市场拓展策略：为了实现全面的市场覆盖，集团将优化现有高层级市场的资源分配，提高市场效率。同时，积极开拓新兴市场，并制定针对海外市场的策略，力求在保持稳健步伐的同时，海外市场可实现破局。集团执行主席兼联席行政总裁李宁先生总结：「国家一系列深化市场改革政策扎实推进将为集团提供公平且更有活力的市场环境、开辟更为广阔成长空间。集团将恪守既定的发展战略，依托品牌的专业运动基因，持续为大众推出优质的体育用品。与此同时，集团将继续深耕中国市场，并乘奥运东风，秉持『一切皆有可能』的精神，推动中国体育产业走向国际舞台。」- 完 -关于李宁有限公司李宁有限公司是中国领先的体育品牌企业之一，以经营李宁品牌专业及休闲运动鞋、服装、器材和配件产品为主。集团总部位于北京，拥有品牌营销、研发、设计、制造、经销及零售能力，目前已于中国建立庞大的零售分销网络以及供应链管理体系。集团致力于成为源自中国并被世界认可的、具有时尚性的国际一流专业运动品牌企业。除核心品牌李宁牌外，集团亦生产、开发、推广、分销、销售多个自有、特许或与集团第三方设立的合资╱联营企业经营的其他品牌体育产品，包括红双喜乒乓球产品、AIGLE（艾高）户外运动用品、Danskin舞蹈和瑜伽时尚健身产品及Kason（凯胜）羽毛球产品。 Copyright 2024 亚太商讯 via SeaPRwire.com.

SHENZHEN, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. In the case that all medicines were directly sold by the Company, the turnover was RMB4,287.5 million, representing a decrease of 22.6% compared with 1H 2023, an increase of 8.9% compared with 2H 2023; Among which, the total revenue of non-National VBP exclusive products and innovative products was RMB2,404.7 million, accounting for 56.1% of CMS’s revenue in the case that all medicines were directly sold by the Company. Profit for the period was RMB903.4 million, representing a decrease of 52.8% compared with 1H 2023, a substantial increase of 92.8% compared with 2H 2023.The year 2024, not only marks the first year of the commercialization of CMS’s innovative products, but also a crucial point for the release of National Volume Based Procurement (“National VBP”) impact on its financial performance. Deanxit entered the seventh batch of National VBP in November 2022, Plendil and Ursofalk entered the eighth batch of National VBP in July 2023, and none of the three original drugs were selected, which had a negative impact on the Company’s business performance. In 1H 2024, the Company’s overall performance showed a growth trend compared with 2H 2023, indicating that CMS has basically digested the impact of National VBP and successfully entered the "New Product Era" where non-national VBP exclusive products and innovative products drive its growth.With the approval for marketing of LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) in June and METOJECT (Methotrexate Injection)’s additional indication of active rheumatoid arthritis (RA) in adults in July this year, CMS's innovative drug portfolio in the commercialization stage has expanded into 5 products (including 6 indications); simultaneously with a rich and differentiated innovative pipeline reserve. Gathering the power of innovation and riding the momentum of development, CMS is comprehensively shaping new drivers for development with a healthier product structure, further opening up a new cycle of quality development.The "Collaborative and In-house" dual-engine R&D model drives the simultaneous improvement in quantity and quality of the pipeline, accelerating the transformation of innovative biotechnologyA profound innovative drug R&D pipeline is an important driving force for the long-term development of CMS. The Company adheres to the purpose of innovation for meeting the unmet clinical needs and solving the difficulties of patient medication, and promotes innovation development through a two-wheel drive of “Collaborative R&D and In-house R&D”, continuously deploying FIC (first-in-class) and BIC (best-in-class) innovative products, and enhancing the capabilities and efficiency of research and clinical development to achieve a rapid transformation of scientific outcomes into social and commercial values.As of now, CMS's innovative product portfolio approved for marketing in China has been expanded into 5 products (including 6 indications), among which, 4 innovative drugs (VALTOCO, ILUMETRI, METOJECT - psoriasis indication, VELPHORO) have been included in the National Reimbursement Drug List (NRDL) and entered large-scale clinical application; also, CMS newly added LUMEBLUE and METOJECT (RA), for being approved for marketing in China recently.CMS has also steadily advanced the clinical development of innovative products. Currently, Desidustat Tablets is under NDA review in China; Also, a total of about 10 projects have been prepared/launched for their registrational clinical trials, mainly randomized controlled trials (RCT).At the same time, the Company had continued to strengthen basic research and independent innovation capabilities, and successfully promoted more than 10 in-house R&D projects, among which, three innovative drugs (VEGFA/ANG2 Tetravalent Bispecific Antibody, Highly Selective TYK2 Inhibitor CMS-D001 Tablets, and GnRH Receptor Antagonist CMS-D002 Capsules) have entered the clinical development stage.In addition, the Company’s innovative pipeline has continued to expand. CMS Skinhealth collaborated with Incyte once again, and has obtained exclusive license to research, develop, register and commercialize povorcitinib, a selective oral small-molecule JAK1 inhibitor, in countries/territories including Mainland China, Hong Kong, Macau, Taiwan Region and 11 Southeast Asian countries. This further enriched the product portfolio of CMS Skinhealth in the treatment of vitiligo and other immune-mediated dermatology diseases.Subsequently, CMS will continue to produce innovative products with higher efficiency and more controllable costs every year, accelerating the release of innovative value and embracing quality and sustainable performance growth through a healthy product structure dominated by non-National VBP exclusive products and innovative products.Successful commercialization system releases the clinical value of innovative products in an efficient and collaborative mannerAfter 32 years of deep cultivation in specialty therapeutical fields, successful commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, it has achieved in-depth development of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology, and ophthalmology, and expanded its boundaries in related fields. Additionally, the Company established a highly qualified, professional promotion team with strong execution, as well as extensive channel and resource coverage, which has laid a solid foundation for the rapid market entry and brand building of its innovative products.Four innovative drugs of CMS have entered large-scale clinical applications, covering various disease fields such as central nervous system, dermatology, nephrology, and gastroenterology, and developed synergistically with the existing marketed products in promotion team and channels. Meanwhile, leveraging on the opportunity of being included in the NRDL, CMS is advancing hospital development, brand building, real world studies and medically-driven academic promotion. CMS is improving patients’ accessibility to innovative drugs with the help of patient aid and disease knowledge popularization programs, promoting the release of products’ clinical value.The Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to light medical aesthetic products and dermatology-grade skincare products, continuously improving the construction of a full life-cycle skin-health management platform covering dermatological treatment, skincare, and medical aesthetics through internal development and external collaboration. In terms of clinical development of dermatology prescription drugs, CMS has completed the Pivotal Real World Study for ruxolibinib cream in vitiligo, and is advancing the registration application process in Mainland China. At the same time, it has continuously complemented the regenerative light medical aesthetic portfolio, among which the China’s medical device registration application of the Poly-L-lactic Acid Microparticle Filler Injection has been accepted by the NMPA during the Reporting Period; and the Company has newly obtained exclusive licenses of three regenerative light medical aesthetic products (Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant), which are currently under the registrational clinical trial stage in China.The results announcement shows that, as of the end of June, the promotion network of CMS has covered over 55,000 hospitals and medical institutions, and approximately 280 thousand retail pharmacies in China.Leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, nephrology, ophthalmology, dermatology and other specialty therapeutical fields, CMS steadily releases the scale effect of its specialty businesses, and builds high competition barriers, creating broad commercial potential for its innovative products and exclusive products.Drawing up the internationalization layout to gather momentum for the incremental marketIntegrating the advantageous resources of the Company, its Southeast Asia business “Rxilient Health”, shares and expands the successful experience of CMS gained from the China market, as well as global quality products and innovative technological resources, into the Southeast Asia market. This accelerates the improvement of the platform integrating “R&D, manufacture, and commercialization” of the Southeast Asia business, empowering Chinese and global pharmaceutical companies to implement the “overseas development” strategy, and also opening up a larger space for incremental development opportunities for CMS.As of the end of June, Rxilient Health has established a competitive product portfolio with more than ten differentiated products, covering therapeutic areas such as oncology, central nervous system, autoimmune, dermatology, and ophthalmology, etc. Rxilient Health is accelerating the relevant work on the market registration processes in Southeast Asian countries for innovative pipeline products, such as ruxolitinib cream, Methylthioninium Chloride Enteric-coated Sustained-release Tablets, and Diazepam Nasal Spray, etc. Furthermore, Rxilient Health collaborated with Junshi Biosciences to promote the registration process of toripalimab (anti-PD-1 monoclonal antibody) in multiple countries in Southeast Asia, aiming to benefit local cancer patients as soon as possible.In December last year, the Company and Rxilient Health joined hands with Pharmaron and other partners to complete the purchase of the Singapore manufacturing plant. This year, all relevant parties have been orderly advancing a series of work for the Singapore manufacturing plant, including equipment testing, quality verification, and production quality system certification, etc., so as to accelerate the CDMO business development, and to optimize the Company’s overseas supply chain and manufacturing capabilities. The business layout will further facilitate more inter-industry cooperation between CMS and global partners in the future, thus jointly building a win-win medical innovation ecosystem with mutual benefits.ConclusionSince its establishment in 1992, CMS has followed the development pattern of the industry and has promoted three significant strategic transformations successfully with a forward-looking vision. The Company started as an agent of imported original drugs, gradually developed to control the rights of original/exclusive products, and then achieved a comprehensive innovative transformation. Each step of the transformation is in sync with the industry development trends. CMS steadily aims towards the ultimate goal, and constantly builds up its strength and resilience to persist through the industry development cycle. With the gradual release of the impact of national VBP on its financial performance, CMS has been transforming into a brand-new company. While embracing the innovation achievements in each stage, CMS is fully prepared for a sustainable and healthier development in the future.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

FINANCIAL HIGHLIGHTS- In the first half of the year, the Group recorded the following operating results:  – Revenue rose by 2.3% to RMB14,345 million; gross profit margin rose by 1.6 percentage points to 50.4%  – Net operating cash inflow increased by 40.6% to RMB2,730 million  – Net profit attributable to equity holders of the Company was RMB1,952 million with net profit margin of 13.6%, and EBITDA margin was 24.0%- Working capital remained at a healthy level:  – The percentage of gross average working capital to revenue was 7.1%  – The cash conversion cycle was 31 days, representing an increase of 1 day as compared to the same period last year- The Board resolved to declare an interim dividend of RMB37.75 cents per ordinary share of the Company issued or to be issued upon conversion of convertible securities for the six months ended 30 June 2024.OPERATIONAL HIGHLIGHTS- The retail sell-through for the overall platform decreased by low-single-digit, including online and offline channels- Channel inventory increased by mid-single-digit comparing to the same period last year. The inventory turnover and ageing structure remained at a healthy level- Offline channel new product sell-through decreased by mid-single-digitHONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - Li Ning Company Limited (stock codes: 2331 (HKD counter) and 82331 (RMB counter)) announces today its 2024 interim results for the six months ended 30 June 2024.Financial ResultsIn the first half of 2024, China’s economy demonstrated an orderly recovery, with favorable national policies continuously injecting vitality into the market. Against the backdrop of the rising public health awareness, numerous international and national events have spurred public’s enthusiasm for sports. Currently, overall consumer confidence still has room for recovery, and the market is in a gradual and positive adjustment phase.Leveraging the brand’s professional sports background, the Group maximizes its insights into the sports industry, understanding of sports categories, and technological innovation capabilities, concentrating on five core categories of running, basketball, fitness, badminton, and sports casual during the Reporting Period. Through continuous research and development (“R&D”) investment and technological innovation, the Group consistently enhances product capabilities, optimizes consumer experience, and ensures sustainable development in the long run while expanding the Group’s business.In the first half of 2024, the Group’s overall performance remained stable with pragmatic growth. During the Reporting Period, revenue amounted to RMB14,345 million, representing an increase of 2.3% as compared to the corresponding period of 2023 (2023 H1: RMB14,019 million). Gross profit increased by 5.8% from RMB 6,839 million in the same period of 2023 to RMB 7,236 million, and the overall gross profit margin was 50.4% (2023 H1:48.8%), the gross profit margin increased by 1.6 percentage points as compared to the corresponding period of last year. Basic earnings per share was RMB75.80 cents (2023 H1: RMB80.63 cents). The Board resolved to declare an interim dividend of RMB37.75 cents (2023 H1: RMB36.20 cents) per ordinary share of the Company issued or to be issued upon conversion of convertible securities for the six months ended 30 June 2024. The interim dividend payout ratio is 50%.In terms of cash flow management, the Group's net cash generated from operating activities during the Reporting Period amounted to RMB2,730 million (2023 H1: RMB1,942 million). As at 30 June 2024, cash and cash equivalents (including cash at banks and in hand, and fixed term deposits with original maturity of no more than three months) amounted to RMB6,147 million, representing a net increase of RMB703 million, as compared with the position as at 31 December 2023. Adding back the amount recorded as fixed-term deposits held at banks, cash balance amounted to RMB17,558 million, which represented a net decrease of RMB417 million as compared to 31 December 2023. During the period, revenue increased year-on-year while the efficiency of settlement remained stable, which, in conjunction with the reasonable purchase and payment plan, contributed to the year-on-year increase in net cash generated from operating activities. The Group will continue to place extra emphasis on its cash flow management to ensure stable development of the Group in the long run.Operational SummaryDuring the Reporting Period, the Group adhered to the core strategy of “Single Brand, Multi-categories, Diversified Channels” focusing on seven major business transformation tracks and continuously strengthening its sports genes to establish a clear professional sports brand positioning. Meanwhile, the Group was efficiently empowered in supply chain management, logistics platform, channel expansion and store upgrading, jointly building a solid foundation for the overall sales of the Group.In terms of technological innovation, in May 2024, the Group successfully held a technology conference with the theme of “In My Name, Tech LI-NING” , which demonstrated that the Group has built two key pillars of product development and innovation consisting of technology R&D and sports science research through long-term accumulation of technological innovation. At the conference, the Group presented its six innovative technologies of “Carbon Core” , “Dual-Stage Assist Curves”, “Super Jiang” , “GCU”, “Super BOOM” and “Extreme Boom Fiber” , and also unveiled three new innovations for the first time: the running shoes of “Shadow 3”, the premium racing shoes of “Dragonflight” and dual-vent nanotechnology for rainstorm protection.In terms of professional products and marketing, the Group continued to focus on the five core categories of running, basketball, badminton, fitness and sports casual, and continued to make efforts in the innovation in sports technology. At the same time, the Group also actively integrated with sports fashion culture, launched sports products with both technology and fashion attributes and continuously enhanced the core competitiveness of products. In addition, the Group actively deployed universal marketing to enhance consumers’ awareness of the Group’s products, continuously enhance brand influence and expand its consumer base.In the midst of a great year for sports, the Group launched a campaign theme “In My Name” , to encourage everyone to engage in sports activities and create their own highlight moments. Through delivering the brand proposition and spirit and telling stories of the athletes from the national gold medal team, top athletes in various categories and sports KOLs, as well as overall demonstrating Li Ning’s technological strength, launching theme series products and creating atmosphere for themes at stores, the Group reinforces the professional brand image of LI-NING, realizes the whole chain from brand proposition to product experience, and deeply connects the brand with each consumer.In terms of supply chain management, the Group constructed an all-round and high-efficiency supply chain ecosystem. It not only deeply explored and expanded high-quality supplier resources for high-end sports and outdoor products to form a strong supplier matrix, but also flexibly responded to market changes with a flexible supply strategy as the core.In terms of logistics management, the Group adopted refined logistics plan management, customized strategies based on the characteristics of the business divisions, and optimized the process of goods warehousing and delivery. Meanwhile, the logistics informationization platform empowered distributors to share information in real time, improved the efficiency of store distribution, and further improved the quality of logistics services.In terms of channel expansion and image upgrading, the Group actively optimized its channel layout, consolidated and expanded its competitive advantage in the high-end market by closing low-efficiency stores and strengthening the renovation and expansion of premium stores. Meanwhile, the active development of emerging markets, the new upgrading of the 9th generation stores, and the successful establishment of premium outlets further enhanced the brand image and market influence. In order to create an immersive experience of key events, 4,238 stores introduced key visual display designs featuring “In My Name” themes and core sports resources in the first half of the year, further enhancing consumers’ visual experience and brand awareness.As of 30 June 2024, the number of conventional stores, flagship stores, China LI-NING stores, LI-NING 1990 stores, factory outlets and brand stores under LI-NING brand (including LI-NING Core Brand and LI-NING YOUNG) amounted to 7,677, representing a net increase of 9 Point-of-sale (“POS”) as compared to 31 December 2023. The number of distributors was 44 (including sales channels of China LI-NING stores), representing a net decrease of 2 as compared to 31 December 2023, demonstrating the Group’s precision and efficiency in channel layout.In terms of retail operation, in the first half of the year, the Group deepened the innovation and practice of the single-store operating model to effectively promote the comprehensive implementation of retail operation standards. The store management efficiency has been significantly improved through the comprehensive promotion of its retail end sales planning system and the implementation of the system in core stores.In terms of new retail business, the Group strengthened community operations and content creation through digital transformation to achieve efficient conversion of private traffic, effectively improving sales and conversion efficiency. In addition, the Group actively explored diversified business models, including attracting traffic through social platforms such as Douyin and online business cooperation with core channels, constantly injecting new momentum into store sales, increasing the proportion of out-of-store sales in stores, and further enhancing the operating efficiency of stores.In respect of the e-commerce operation, the e-commerce of Li Ning continued to focus on breakthroughs in professional functional products, especially achieving rapid growth in the field of running shoes, while professional basketball shoe products also consolidated its market leading position. In addition, in terms of online exclusive IP, the Group has successfully created a number of IP that have gained volume and reputation in the industry. During the period, the Group achieved synergistic growth of e-commerce business and retail operation through effective integration and innovative practices across online and offline channels, driving a significant increase in sales performance and further strengthening of market share.In terms of kidswear business, LI-NING YOUNG comprehensively streamlined the youth product matrix, clarified the core competitiveness of clothing and accessories, and improved the footwear product matrix. For marketing, LI-NING YOUNG consolidated its marketing resources and actively explored omni-channel marketing and community operation. By actively cooperating with basketball star Wade to further increase the brand influence. LI-NING YOUNG also actively actively carried out various member community activities and launched new celebrity athlete in-store opening activities to continuously drive store traffic. As at 30 June 2024, the total number of LI-NING YOUNG POS in China amounted to 1,438, representing a net increase of 33 POS since the end of the previous quarter and a net increase of 10 POS since the beginning of this year. The Group will continue to intensely develop its LI-NING YOUNG business, take a product focused approach to upgrade core product technology and design, advance the exploration of market demands and product categorization and strengthen brand promotion, so as to develop LI-NING YOUNG into a leading professional sportswear brand for kids in China.OutlookThe Group will continue to practice its core strategy of “Single Brand, Multi-categories, Diversified Channels”, persistently strengthen its product capabilities and integrate its operational resources to propel the Group towards stable and enduring growth by leveraging the organizational capability as an efficient corporation:– Develop the fundamental business with stability. The Group will continue to amplify the market influence of the LI-NING brand, focusing on the development of its five core categories including running, basketball, fitness, badminton and sports casual. Through investment in research, development and innovation, the Group will achieve continuous upgrading of its product matrix to meet the growing consumer demand for high-quality and personalized sports equipment, thereby reinforcing and expanding the Group’s market leading position in core areas.– Optimize and upgrade the product structure. The Group will further upgrade its diversified product matrix under the single-brand strategy, aligning with the evolving market trends and consumer preferences. By fully leveraging the complementary functions of “China LI-NING” and “LI-NING 1990” in the sports casual sector, and expanding multiple dressing scenarios, the Group will enhance the competitiveness of its brands in diverse scenarios.– Look to the future and seize opportunities to make a breakthrough. The Group will actively explore breakthroughs and take the lead in entering new tracks in sports consumption. By tapping into the huge potential of the women’s, outdoor and youth markets, formulating targeted marketing strategies and launching products that meet the needs of the target groups, the Group aims to make breakthroughs in these new areas.– Optimize market expansion strategy. To achieve comprehensive market coverage, the Group will optimize the allocation of resources to existing high-level markets to improve market efficiency. Concurrently, by actively exploring emerging markets and formulating strategies for overseas markets, the Group strives to achieve significant breakthroughs in overseas markets while keeping a steady and sustainable momentum.Mr. Li Ning, Executive Chairman and Joint CEO of the Group, concluded, “The country's series of in-depth market reform policies will steadily advance, providing the Group with a fair and more vibrant market environment, and opening up broader growth space. The Group will adhere to its established development strategy, rely on the professional sports genes of its brands and continue to launch high-quality sporting products for the public. At the same time, the Group will continue to cultivate the sports market in China, and ride the wave of the Olympics, upholding the spirit of ‘Anything is Possible’, to propel the Chinese sports industry onto the international stage.”- END -About the GroupLi Ning Company Limited is one of the leading sports brand companies in China, mainly operating professional and leisure footwear, apparel, equipment and accessories under the LI-NING brand. Headquartered in Beijing, the Group has brand marketing, research and development, design, manufacturing, distribution and retail capabilities. It has established an extensive retail distribution network and supply chain management system in China. The Group is committed to be the most prominent, stylish, world-leading sports brand from China.In addition to its core LI-NING brand, the Group also manufactures, develops, markets, distributes, sells various sports products which are selfowned by or licensed to the Group, including Double Happiness (table tennis), AIGLE (outdoor sports), Danskin (fashionable fitness products for dance and yoga) and Kason (badminton), which are operated through joint venture/associate with third parties of the Group. Copyright 2024 ACN Newswire via SeaPRwire.com.

MANILA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - Darwinbox, a global leader in providing end-to-end Human Resources Management Systems (HRMS), has significantly transformed the operations of Security Bank Corporation, one of the largest private domestic universal banks in the Philippines and its subsidiaries.This comes as Darwinbox continues to enhance the HR landscape in the Philippines by helping companies optimize their human resources (HR) and improve overall operational efficiency.Security Bank EVP and Chief People Officer, Nerissa Berba, said that Darwinbox, a new-age, enterprise-ready Human Capital Management (HCM) platform, optimized the bank's processes, reduced manual tasks, and enhanced efficiency with streamlined workflows.Security Bank has already observed significant enhancements in its HR processes thanks to Darwinbox. To date, it has automated close to 90 per cent of HR processes, leading to a 67 per cent increase in HR operational efficiency within the first year, which exceeded the initial projection of 30 per cent. Consequently, this has allowed for a 30 per cent improvement in report generation speed and a 75 per cent reduction in the time taken for performance administration ensuring full compliance with policies.Berba further said that Darwinbox met all the bank’s HCM requirements. First, the entire employee lifecycle, from hire-to-retire, can be managed within Darwinbox, allowing the bank to have one system for all its employees’ needs. The Bank has implemented most of the Darwinbox modules, ensuring a consistent experience across the majority of the organization and HR processes.Additionally, the simplicity and user-friendliness of the Darwinbox interface, along with its deep functionality and intuitive mobile app, add significant value to the Bank’s operations. The no-code backend of the highly configurable platform empowers its HR team to tailor processes to the organization’s needs without external consultants.“[Darwinbox] is truly an empowering platform for an enterprise that is customer-first and people-empowered,” Berba said.Security Bank currently provides banking services across the Philippines through a dedicated workforce of nearly 9,000, who deliver the brand’s promise of ‘BetterBanking’.“Our commitment to a future-ready organization hinged on a compelling employee value proposition and a transformative work culture,” Berba said.Meanwhile, Darwinbox, founded in Asia and currently catering to over 950 enterprises worldwide, is actively expanding its presence in the Philippines.The company plans to engage various sectors, utilizing its advanced HR technology to address the diverse needs of organizations in the region. This expansion is in line with Darwinbox's goal to provide businesses with comprehensive and intuitive HR solutions, specifically designed for the unique challenges and opportunities within the Philippine market.Media Contact:Shruti Parmarshruti@bloomingdalepr.comBloomingdale Public Relations Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 由发展局、国家文物局和澳门特别行政区政府社会文化司合办的「从湾区启航：『南海I号』与海上丝绸之路」展览于八月十五日举行开幕礼。展览展出「南海I号」远洋商船的出土文物及粤港澳三地的相关文物，以展示粤港澳大湾区在海上丝绸之路的角色。开幕礼由发展局局长甯汉豪、中国文物交流中心副主任周宇、广东省文物考古研究院院长曹劲和澳门特别行政区政府文化局副局长郑继明主持。「南海I号」是南宋时期的商舶，至二○○七年被打捞出水，是迄今考古发现保存最完整的古代远洋商船。「南海I号」出土大量文物，主要有瓷器、铜铁器、金银器、漆木器等，其数量、形制、工艺和造型，在南宋时期的考古材料中，均属罕见。考古专家推断「南海I号」于南宋淳熙十年（1183年）或不久以后，在广东往南海的航道上沉没。是次展出的255项展品中，有来自「南海I号」的南海窰酱釉「淳熙十年」印文四系罐、景德镇窰青白釉印花枝梅纹花口碗、龙泉窰青釉刻划莲纹折腰花口碟、金单顶链犀角形锥筒饰项炼、镶宝石空心金镯等。来自粤港澳三地的展品则包括广州南越国宫署遗址出土的宋代湖田窰青白釉墨书「公使」款碗底残件、香港圣山遗址出土的宋代青黄釉龙纹六系罐、澳门圣保禄学院遗址出土的明代景德镇窰青花象首军持等。展览于尖沙咀海防道九龙公园香港文物探知馆举行，展期由八月十六日至明年二月十二日，免费入场。有关展览筹备过程的短片，已上载发展局古物古迹办事处网页（www.amo.gov.hk/tc/news/index_id_153.html?year=2024）。「从湾区启航：『南海I号』与海上丝绸之路」展览于八月十五日举行开幕礼。图示发展局局长甯汉豪（右二）、中国文物交流中心副主任周宇（左二）、广东省文物考古研究院院长曹劲（右一）和澳门特别行政区政府文化局副局长郑继明（左一）主持开幕礼。「从湾区启航：『南海I号』与海上丝绸之路」展览于八月十五日举行开幕礼。图示发展局局长甯汉豪（左一）和中国文物交流中心副主任周宇（右三）及澳门特别行政区政府文化局副局长郑继明（右二）参观展览。「从湾区启航：『南海I号』与海上丝绸之路」展览于八月十五日举行开幕礼。图示图示发展局局长甯汉豪（左一）和中国文物交流中心副主任周宇（左二）及澳门特别行政区政府文化局副局长郑继明（左三）参观展览。南海窑酱釉「淳熙十年」(1183) 印文四系罐，罐上印文对推断「南海 I 号」沉没时间至关重要。南宋(1127-1279)镶宝石空心金镯，「南海I号」出土，沙特阿拉伯利雅德也有类似的器物出土。南宋(1127-1279)龙泉窑青釉刻划莲纹折腰花口碟，「南海I号」出土。  Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 中国辣味休闲食品行业龙头企业，卫龙美味全球控股有限公司（「卫龙美味」或「集团」）及附属公司（「集团」）（香港联交所股票代码：09985）公布截至2024年6月30日止六个月（「期内」）未经审核之中期业绩。2024年上半年，全球不确定性因素增多背景下，中国经济维持稳健增长势头。得益于以Z世代为首的年轻消费群体日益增高的消费意愿，休闲食品产业的成长动力强劲。回顾期内，卫龙美味紧握多元化主流消费观念带来的零食领域的结构性机会，坚定「多品类大单品」产品策略并持续提升研发能力，积极开展线上线下组合式营销活动以提升品牌影响力，全力推进全渠道策略落地实施，进而为消费者提供更满意、更便利、更好的消费体验。报告期内，卫龙美味经营策略收效明显，业绩持续向好，营收净利实现双位数增长。2024年上半年实现总收入约29.39亿元（人民币，下同），同比增长26.3%，主要得益于集团期内有效实施各项业务发展策略，特别是积极推进全渠道建设和品牌建设，线上线下收入均有稳步提升。受惠于期内产能利用率提升及部分原材料价格下降，集团录得毛利为约14.62亿元，同比增长32.2%，毛利率由去年同期47.5%提升2.3个百分点至49.8%。集团期内净利润同比大幅增长38.9%至约6.21亿元。在收入及毛利率提升的推动下，净利率较上年同期提升了1.9个百分点至21.1%。基于期内整体绩效表现，集团董事会决议派发2024年中期股息每股人民币0.16元（含税，共计中期股息约3.76亿元），约为2024年上半年净利润的60%，预计派付股息日期为2024年10月18日或前后。产品方面，集团坚持以消费者体验为中心，坚持「多品类、大单品」产品策略，积极提升产品研发能力，持续挖掘年轻消费群体的消费喜好变化，先后推出「小魔女」香辣烧烤味魔芋素板筋，「小魔女」酸辣火锅味魔芋素毛肚，及「脆火火」青柠味辣脆片等产品，进一步扩大产品组合，以满足消费者多样化、个性化等各方面的需求。品牌建设方面，集团持续加强品牌建设，积极通过开展线上线下组合式品牌及营销活动加强与消费者的互动，以提升品牌影响力，譬如核心大单品「魔芋爽」的品牌传播、「小魔女」IP动画视频、「榴莲辣条」快闪店、「蛋仔派对」联名亲嘴烧等各种好玩有趣的营销活动。集团积极打造与众不同的品牌年轻化之路，以不断增加品牌的活力和吸引力，让品牌更贴近年轻消费群体的生活方式和消费习惯。渠道方面，集团积极推进全渠道策略的落地实施，在巩固传统零食渠道布局的同时，紧握O2O、内容电商、零食量贩店、仓储会员店等新兴渠道带来的增长机遇。报告期内，集团深耕线上线下全渠道建设，与消费者建立了更加紧密的联系，提供了更便利的消费体验。卫龙美味董事长刘卫平先生表示：「作为中国辣味休闲食品行业的领导者和先行者，集团坚持以更积极、更开放的心态拥抱多元化的消费喜好变化，积极加强品类创新和产品创新、推进年轻化多样化的品牌建设、抓住新型渠道发展红利的同时夯实传统渠道、坚定产品创新和全渠道建设、坚持供应链品质与效率的有效提升，持续打造为消费者提供更多价值的辣味休闲食品龙头企业。集团将继续不忘初心、牢记使命，致力为消费者、客户、股东、投资者、员工及社会创造最大的价值回报。」人民币截至6月30日止六个月变动2024年2023年收入29.39亿23.27亿+26.3%毛利14.62亿11.06亿+32.2%毛利率49.8%47.5%+2.3个百分点期内利润6.21亿4.47亿+38.9%净利润率21.1%19.2%+1.9个百分点每股基本盈利0.27元0.19元+42.1%中期股息    0.16元/普通股0.12元/普通股+33.3%- 完 -关于卫龙美味全球控股有限公司卫龙美味全球控股有限公司（「卫龙美味」）是中国领先的集研发、生产及销售为一体的辣味休闲食品企业，拥有强劲的增长势头和颇具影响力的品牌。卫龙美味以传统美食为基础开创了中国调味面制品（俗称「辣条」）行业，于2001年开创出第一根辣条，并引领了辣条行业标准建设。凭借出众的品类拓展能力，本集团已成功扩展至蔬菜制品、豆制品及其它产品等品类，推出了包括魔芋爽、风吃海带、溏心蛋等大单品。本集团又相继推出麻辣辣条、魔芋素毛肚「小魔女」及辣脆片「脆火火」等新品，深受消费者的喜爱。卫龙美味是倍受中国年轻消费者喜爱的休闲食品品牌，拥有有效触达年轻消费者的全渠道销售及经销网络。2024年我们荣获FBIF WOW食品创新奖「年度创新休闲零食奖」，同时亦获得「胡润国潮品牌百强榜」奖项。如欲获得更多资讯，请浏览https://www.weilongshipin.com/。 Copyright 2024 亚太商讯 via SeaPRwire.com.

财务摘要︰- 2024年上半年总收入人民币18.67亿元，同比增长27.1%  - 先知AI平台业务收入为人民币 12.51亿元，同比增长65.4%，占总收入的比例升至67.0%  - SHIFT智能解决方案业务收入为人民币4.53亿元，占总收入的24.3%  - 式说AIGS服务业务收入为人民币1.63亿元，占总收入的8.7%- 2024年上半年毛利为人民币7.90亿元，同比增长12.1%，毛利率为42.3%- 2024年上半年研发投入超人民币8.50亿元，研发费用率超45.5%- 2024年上半年经调净亏损额同比收窄4.0%，经调净亏损率同比收窄至9.0%营运摘要：- 2024年上半年，总用户数185个，标杆用户数86个，覆盖14个行业，标杆用户群体平均营收贡献为人民币1,148万元，同比增长26.9%。- 先知AI平台：报告期内，发布了“第四范式先知AI平台5.0”，定位行业大模型开发及管理平台，以提升企业核心竞争力为目标；通过“先知 Inside 模式”，将先知AI平台内的核心技术，作为引擎，结合不同行业的多场景需求，打造智能化产品或解决方案；基于“先知AI平台”的核心能力，携手“范生态”伙伴，高效打造超30款人工智能产品，截至2024年8月1日，已覆盖超20个行业的研产供销服等各类场景- SHIFT智能解决方案：目前，已推出了搜广推一体化平台“天枢”、大模型纳管平台Model Hub、数据查询、智能问数、软件操作助手（Copilot）等应用产品- 式说AIGS服务：报告期内，持续迭代和优化产品功能，更加注重为开发者提供高效、便捷的操作习惯及程序设计体验。在功能层面，产品进一步优化沉浸式编码体验，开发者无需离开开发环境，直接查询所需业务、技术文档，并提高代码编写的效率和质量香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 领先的企业级人工智能软件公司——北京第四范式人工智能技术股份有限公司（“第四范式”或“公司”，股份代号：6682.HK），公布截至2024年6月30日止六个月（“报告期内”）的综合业绩。2024年上半年，第四范式营收稳健增长，盈利节奏清晰，总收入人民币18.67亿元，同比增长27.1%。毛利润人民币7.90亿元，同比增长12.1%，毛利率为42.3%。在保证高研发投入的基础上，继续保持清晰减亏趋势，上半年研发投入人民币8.50亿元，研发费用率45.5%；经调净亏损额同比收窄4.0%，经调净亏损率同比收窄至9.0%。2024年上半年，第四范式坚持推动客户群体多元化，持续巩固在交通运输、能源电力、金融、运营商等重点行业的领先地位，报告期内已覆盖14大行业，总用户数185个，标杆用户数86个，标杆用户平均收入为人民币1,148万元 ，同比增长26.9%。报告期内，第四范式核心业务“第四范式先知AI平台”继续保持强增长态势，该业务收入人民币12.51亿，同比增长65.4%，占总收入比已达 67.0%。该业务上半年规模化应用与产品生态力拓展并重，已支撑第四范式行业大模型在14个行业规模化应用；同时该业务通过人工智能技术产品化的方式，为各行业产出超30款人工智能产品，未来也将继续通过产品矩阵，打造AI产品生态，推进业务增长。行业大模型+先知AI产品生态双引擎   驱动核心业务持续暴涨65.4%先知Inside产品矩阵：用高质量人工智能产品力，拓展第四范式生态2024年上半年，第四范式创新式的通过“人工智能技术产品化”的方式，围绕核心业务先知AI平台能力，以“先知Inside”模式为引擎推出多维度、多层次的人工智能产品，拓展人工智能应用边界，构建第四范式产业生态。通过“先知 Inside 模式”，先知AI平台内的核心技术，第四范式可以结合不同行业的多场景需求，打造智能化产品或解决方案。第四范式将先知AI平台的人工智能基础能力，进行产品化输出，构建出可应用不同场景的人工智能产品矩阵，用以人工智能产品为核心的“范生态”，帮助生态合作伙伴及其产品实现服务质效双增长，拓展人工智能技术赋能千行万业的形态。上半年，公司基于先知AI平台核心能力，携手“范生态”伙伴，高效打造超30款人工智能产品，截至2024年8月1日，已覆盖超20个行业的研产供销服等各类场景。涉及大模型语音合成、物理仿真、多模态生成、AutoML视觉检测、搜广推等人工智能技术领域。AI数字人视频合成平台、vGPU资源池化、5G视频营销、AI质检系统、三维扫描建模设备等多款人工智能产品已在企业中形成多场景应用。行业大模型：规模化能力凸显 已落地14大行业发展10年来，第四范式先知AI平台完成了从1.0版本到先知AI平台5.0版本的迭代。今年最新发布的“第四范式先知AI平台5.0”定位为行业大模型开发及管理平台。平台以提升企业核心竞争力为目标，在支持接入企业各类模态数据的基础上，提供大模型训练、精调等低门坎建模工具、科学家创新服务体系、北极星策略管理平台、大模型纳管平台、主流算力适配优化等能力，实现端到端的行业大模型的构建、部署、管理服务。报告期内，基于“第四范式先知AI平台 5.0”能力，第四范式与标杆用户及合作伙伴，规模化打造了学术翻译、健康管理、水电管理、水利、3D辅助设计、供应链、流体动力等诸多领域行业大模型，覆盖交通运输、数据中心、金融、能源电力、运营商、信息技术、智能制造、零售等14大行业，高效赋能企业多场景、高价值数字化转型，稳步推进人工智能技术在千行百业的规模化应用。未来，随着先知AI平台能力的持续提升，第四范式将持续深入探索行业大模型在企业服务领域的高价值应用场景，通过规模化应用与产品生态力的拓展，加速推进人工智能产业落地进程。在战略展望方面，第四范式董事会主席、执行董事、首席执行官兼总经理戴文渊博士表示：“第四范式创立近10年，秉承创新驱动发展，致力于用‘第四范式’技术理论，赋能千行万业，为人工智能技术的发展贡献力量。报告期内，我们致力于用创新驱动人工智能技术多元应用，将人工智能技术产品化输出，上半年为各行业高效打造30多款人工智能产品，我们基于先知AI平台的核心能力，携手‘范生态’伙伴，截至2024年8月1日，已覆盖超20个行业的研产供销服等各类场景，用高质量产品构建人工智能产业生态。未来，我们将继续以技术创新为支撑，输出高质量产品矩阵，打造AI产品生态，在推进业务增长的同时，多元化提升千行万业的人工智能应用效率与核心竞争力。” Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月15日 - (亚太商讯 via SeaPRwire.com) – 越秀房地产投资信托基金（「越秀房产基金」，连同越秀房托资产管理有限公司，统称「基金」；股份代号：405）公布其截至2024年6月30日止六个月之中期业绩。越秀房产基金管理团队：主席兼行政总裁及执行董事林德良先生（左二）、副行政总裁及执行董事区海晶女士（左三）、财务总监关志辉先生（左一）、投资者关系总监姜永进先生（左四）2024年中期业绩摘要：- 整体经营稳定，收入总额为人民币10.34亿元（2023年同期：人民币10.61亿元）。- 中期分派每个基金单位约人民币0.0371元，约等于0.0405港元。按年计算的分派收益率为8.52%。- 于2024年6月30日，物业整体出租率为84.0%，维持去年同期水平。广州国金中心：- 广州国金中心综合体录得经营收入为人民币5.04亿元，占基金收入48.8%。- 广州国金中心写字楼成功续约多家重要客户，续约率高达88.2%。- 「国金天地」上半年商场客流量同比增长5%。- 四季酒店国际客源比例大幅提升，雅诗阁公寓实现整体营收再创历史新高。广州越秀金融大厦：- 越秀金融大厦录得经营收入约人民币1.82亿元，占基金收入17.6%，出租率达82.9%。- 上半年成功稳定重点优质租户的续租，空置单元改造去化率高达86%，租户结构持续向好。积极管理融资风险，有效减低融资成本- 针对年内到期债务，管理人提前筹划，于2月引入人民币5.3亿元境外循环贷款，固定利率3.70%，于5月引入11.2亿港元境内银行离岸贷款，置换今年到期融资，确保流动性风险得到有效管控。- 管理人把握人民币融资成本利差窗口，陆续以人民币贷款置换存量境外外币融资。截至2024年6月末，已累计引入73.8亿人民币融资并用于置换港元融资，平均成本率为4.55%，同比下降35个基点。- 管理人持续通过融资结构调整，适时增加低成本人民币融资占比的方式。2024年6月末房产基金人民币融资约84.04亿元，占总体融资上升至41%。越秀房产基金主席兼行政总裁及执行董事林德良先生表示：「2024年上半年国内经济增量主要靠供给侧拉动，整体有效需求不足。管理人重点聚焦写字楼、零售商业及酒店公寓三个核心业态，从市场趋势中挖需求找机会，从自身问题剖析中找方向求突破，在激烈市场竞争中推行有效之租赁策略及经营措施，务求为基金持有人交出合格答卷。」国金中心国金中心上半年顶住写字楼市场下行压力，成功续约「英国领事馆」、「苏黎世财险」、「融捷集团」、「CBD管委会」等重要客户，续约率高达88.2%，有效稳定优质客户资源。持续优化租户结构，引进「策略律所」、「申港证券」、「中原环保」等多家名企，并促成楼内实力客户「冠领律所」扩租1,071平方米。为引入大面积优质客户，国金中心主动推进单元整合，提升高区去化效率，目前全层单元已储备约1万平方米客户进入商务谈判阶段。「国金天地」积极调整经营品类，主动汰换低坪效商户，优化项目餐饮组合。上半年引进珠江新城首店新奇烘焙品牌「酵社」、广州首家直营「Subway」形象店、高端商务连锁咖啡品牌「M Stand」及潮牌零食零售「CURIOUS SNACKS」，商场品牌丰富度和关注度持续拉升。推广方面，籍「国金天地」开业八周年之际，推出「粤语音乐节&微醺市集&摇摆舞会」营销活动，扩大宣传声量和触达率。上半年商场客流量同比增长5%。四季酒店在本地奢华市场继续保持领先地位，连续九年荣获「福布斯旅游指南五星级酒店」殊荣。上半年平均入住率为79.0%，酒店国际客源比例大幅提升，有效补充国内市场需求下滑的缺口；平均房价为人民币2,214元，同比增长0.5%。雅诗阁公寓发挥其大户型在短住市场的差异化产品竞争优势，实现整体营收突破天花板，再创历史新高。上半年平均入住率为90.5%，同比增长0.2个百分点；平均房价为人民币1,134元，同比增长3.0%。公寓RevPAR竞争指数达146.3，在竞争市场中保持高位，继续领跑第一梯队。越秀金融大厦越秀金融大厦上半年共完成7,454平方米续租合同，稳定「光大证券」、「国元证券」、「中期期货」及「五矿地产」等重点优质租户的续租，并采取调整楼层、缩减面积等措施，成功挽留三家到期不续客户在项目内调整。空置单元改造去化率高达86%，引进大型律所品牌「数科律所」及两家知名优质金融机构，租户结构持续向好。白马大厦白马大厦对标竞品市场优质品牌，加强客户挖掘及储备，重点解决风险楼层及区域的经营及优化问题，实现招商稳商双轮驱动，上半年平均出租率95.7%，保持高位运行。上半年白马创新营销策略，继续联动政府及行业资源，打造品牌影响力系列工程。组团参加上海服博会CHIC，举办白马无限形态二〇二四秋冬联合订货会，白马品牌在国内外的传播覆盖持续增强。财富广场、城建大厦财富广场租户结构进一步优化，引入行业头部企业「中顺洁柔」，首层街铺无缝衔接进驻「可俊」港式茶餐厅。城建大厦迎来一家政府体育服务机构，去化楼内空置面积约2,500平方米，拉动出租率同比提升5.8个百分点，同时顺利续约「柯尼卡美能达」、「大信会计师事务所」等重要客户，上半年录得87.9%的较高续约率。维多利广场维多利广场实现上半年新签面积1,033平方米，突破困难单元招商，引入实力美容品牌进驻。积极争取外部资源投放，配合主力客户产品上新及活动铺排节奏，助力「优衣库」经营业绩。通过聚焦上半年节日消费特性，刺激顾客到店消费，上半年客流量同比提升14%。上海越秀大厦上海越秀大厦上半年新签面积3,400平方米，引入「长安福特」、「太平保险」等知名企业，顺利续租「理资堂」、「苏尔寿」等优质客户。针对竹园地区有效租赁需求不足，访客量较少的问题，主动拓展招商渠道，同时优化改善产品，选取重点单元投入带精装或家具、遗留装修单元投入翻新，提升来访量和中盘率。武汉物业越秀财富中心上半年共完成新签面积1.7万平方米，并顺利续租「泸州老窖」、「中英人寿」、「广东广信」等优质客户。面对武汉市场净吸纳量低迷、空置率持续高企之困局，越秀财富中心适时检视租赁政策定价，调整佣金政策及主动拓展管道，重点挖掘同区域内的优质客户，提升五大行渠道对项目的带看量，同时加强风险管控。星汇维港购物中心持续优化业态组合，上半年签约「小米」、「隐星空」及「新东方」等品牌，增加培训教育和零售类面积占比，通过持续优化业态组合，活跃整体零售氛围。上半年商场客流量同比增长37.6%，销售额同比增加16.2%。杭州维多利杭州维多利有效化解大面积退租风险，上半年完成两个整层客户招商新签，合同有效租金对比上手分别增加20%和12%。续租管理方面，则完成楼内优质客户「山西路桥」、「中国银行」及「益起玩」等续签，保证现有优质客户稳定经营。未来展望2024年下半年，管理人预计投入资金三千八百多万元人民币，积极推进资产增值工程，实现物业保值增值。融资方面，管理人采取一系列流动性管理措施，将年利率控制在合理水平，并关注汇兑风险。鉴于利率继续维持高位，再融资策略仍将聚焦以低成本境内人民币融资置换外币融资为主。同时，管理人将采取稳健的财务政策，以满足越秀房产基金的营运需要及分派。– 完 –关于越秀房地产投资信托基金越秀房地产投资信托基金（「越秀房产基金」）于2005年12月21日在香港联交所上市，为全球首只投资于中国内地物业的上市房地产投资信托基金。越秀房产基金目前持有的物业组合包括位于广州的广州国际金融中心、白马大厦、财富广场、城建大厦、维多利广场、越秀金融大厦、位于上海的越秀大厦、位于武汉的武汉物业（包括武汉越秀财富中心和星汇维港购物中心）、位于杭州的维多利商务中心以及位于香港的越秀大厦共10项高素质物业，物业产权面积共约118.4万平方米，分别位于中国广州市、上海市、武汉市、杭州市及香港市的核心商业区域。物业类型包括甲级写字楼、商业综合体、零售商业、酒店、服务式公寓、服装专业市场等。传媒查询:纵横财经公关顾问有限公司李惠儿, 电话: +852 2864 4834梁家仪, 电话: +852 2114 4172杨丽明, 电话: +852 2864 4833电邮：sprg_yx@sprg.com.hk网址: http://www.sprg.com.hk Copyright 2024 亚太商讯 via SeaPRwire.com.

SAN DIEGO, CA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Coast Guard (JCG) has signed a contract for the purchase of two SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI), scheduled for delivery in 2025. This follows JCG's ongoing Company-Owned, Contractor-Operated agreement with GA-ASI for operating SeaGuardian, which began in April 2022."Since JCG started operating SeaGuardians, they have been used for various JCG missions, including supporting search and rescue and disaster response, specifically during the 7.6 magnitude earthquake early this year near the Noto Peninsula of Ishikawa Prefecture and maritime surveillance during the 2023 G-7 Summit in Hiroshima, and the system has performed efficiently and effectively," said GA-ASI CEO Linden Blue.SeaGuardian is a medium-altitude, long-endurance RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - The opening ceremony of the exhibition entitled "Launch from Greater Bay Area: Nanhai I Shipwreck and the Maritime Silk Road", co-organised by the Development Bureau (DEVB), the National Cultural Heritage Administration and the Secretariat for Social Affairs and Culture of the Government of the Macao Special Administrative Region, was held on August 15. Featuring artefacts discovered from Nanhai I, an ocean-going merchant ship, and relevant artefacts from Guangdong, Hong Kong and Macao, the exhibition showcases the role of the Guangdong-Hong Kong-Macao Greater Bay Area on the Maritime Silk Road.  The opening ceremony was officiated by the Secretary for Development, Ms Bernadette Linn; Deputy Director of Art Exhibitions China Ms Zhou Yu; the President of the Guangdong Provincial Institute of Cultural Relics and Archaeology, Ms Cao Jin; and the Vice President of the Cultural Affairs Bureau of the Government of the Macao Special Administrative Region, Mr Cheang Kai-meng.Nanhai I was a merchant ship of the Southern Song dynasty. Its shipwreck was salvaged in 2007 and is the most complete ancient ocean-going merchant ship discovered through archaeological excavation to date. A large collection of artefacts was discovered from Nanhai I, mainly porcelain, bronzeware, ironware, gold, silverware, lacquerware and woodenware. The quantities, shapes, craftsmanship and forms of the artefacts are rare among the archaeological finds of the Southern Song dynasty. Archaeologists believe that Nanhai I might have sunk along the maritime route from Guangdong to the South China Sea in the 10th year of the Chunxi reign (1183) of the Southern Song dynasty or shortly afterwards.  Among the 255 items of exhibits are artefacts discovered from Nanhai I, including a brown glazed jar with four lugs and stamped with the Chinese characters “Chun Xi Shi Nian” (i.e. the 10th year of the Chunxi reign) from the Nanhai kiln; a qingbai glazed foliated bowl with stamped plum blossom pattern from the Jingdezhen kiln; a green glazed ogee-shaped foliated dish with incised lotus pattern from the Longquan kiln; a necklace with gold chain and rhinoceros horn-shaped cone ornaments; and a gem-set hollow gold bracelet. Also on display are relevant exhibits unearthed from Guangdong, Hong Kong and Macao, including the bottom fragment of a qingbai glazed bowl with inked Chinese characters “Gong Shi” (i.e. envoy) from the Hutian kiln of the Song dynasty from the site of the Nanyue Kingdom Palace in Guangzhou; a yellowish-green glazed jar with six lugs and dragon pattern of the Song dynasty from the site of the former Sacred Hill in Hong Kong; and a blue-and-white kendi with elephant head shaped spout from the Jingdezhen kiln of the Ming dynasty from the site of St. Paul's College in Macao.The exhibition will run at the Hong Kong Heritage Discovery Centre, Kowloon Park, Haiphong Road, Tsim Sha Tsui, from August 16 to February 12 next year. Admission is free. A short video about the preparation of the exhibition is available on the website of the Antiquities and Monuments Office of the DEVB (www.amo.gov.hk/en/news/index_id_153.html?year=2024).  The exhibition entitled “Launch from Greater Bay Area: Nanhai I Shipwreckand the Maritime Silk Road” opened on August 15. Photo shows the Secretaryfor Development, Ms Bernadette Linn (second right); the Deputy Directorof Art Exhibitions China, Ms Zhou Yu (second left); the President ofGuangdong Provincial Institute of Cultural Relics and Archaeology,Ms Cao Jin (first right); and the Vice President of the CulturalAffairs Bureau of the Government of the Macao Special AdministrativeRegion, Mr Cheang Kai-meng (first left), officiating at the opening ceremony.The exhibition entitled “Launch from Greater Bay Area: Nanhai I Shipwreckand the Maritime Silk Road” opened on August 15. Photo shows the Secretaryfor Development, Ms Bernadette Linn (first left), the Deputy Directorof Art Exhibitions China, Ms Zhou Yu (third right), and the VicePresident of the Cultural Affairs Bureau of the Governmentof the Macao Special Administrative Region, Mr Cheang Kai-meng(second right) touring the exhibition.The exhibition entitled “Launch from Greater Bay Area: Nanhai I Shipwreckand the Maritime Silk Road” opened on August 15. Photo shows theSecretary for Development, Ms Bernadette Linn (first left), the DeputyDirector of Art Exhibitions China, Ms Zhou Yu (second left), and theVice President of the Cultural Affairs Bureau of the Government of theMacao Special Administrative Region, Mr Cheang Kai-meng (third left)touring the exhibition.Brown glazed jar with four lugs and stamped Chinesecharacters “Chun Xi Shi Nian” (i.e. the tenth yearof the Chunxi reign) from Nanhai kiln. The inscriptionon the jar is crucial for determining when the"Nanhai I" sank.Gem-set hollow gold bracelet with sophisticated techniques of SouthernSong dynasty (1127-1279) unearthed at “Nanhai I”, similarartefacts were also found at Riyadh, Saudi Arabi.Green glazed ogee-shaped foliated dish with incised lotus pattern ofSouthern Song dynasty (1127-1279) from Longquan kiln unearthed at “Nanhai I”.  Copyright 2024 ACN Newswire via SeaPRwire.com.